Vasculitis Treatments
Find Vasculitis Treatments
Fasenra
What is Fasenra (Benralizumab)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.
Summary: The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Background: Hypereosinophilic syndrome (HES) is a blood disorder that causes high levels of white blood cells called eosinophils. HES can damage the lungs and airways, intestines, skin, and other organs. The current primary treatment for HES can cause serious side effects. Secondary treatments do not work in all people.
Related Latest Advances
Brand Information
- 10 mg/0.5 mL solution in a single-dose prefilled syringe.
- 30 mg/mL solution in a single-dose prefilled syringe.
- 30 mg/mL solution in a single-dose autoinjector FASENRA PEN.
- Hypersensitivity Reactions
- Carton contains one 10 mg/0.5 mL single-dose prefilled syringe with a gray plunger rod: NDC 0310-1745-01
- Carton contains one 30 mg/mL single-dose prefilled syringe with a blue plunger rod: NDC 0310-1730-30
- Carton contains one 30 mg/mL single-dose autoinjector: NDC 0310-1830-30







